Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

ABIONYX Pharma - Filing #831404

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Reserve of exchange differences on translation	—	—	—	103,000 EUR	—	—	—	—	126,000 EUR	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	—	—	—	7 948 EUR	—	—	—	—	8 251 EUR	—	—	—	—	—	—	—
Current assets	—	—	—	6 886 EUR	—	—	—	—	7 572 EUR	—	—	—	—	—	—	—
Non-current liabilities	—	—	—	2 987 EUR	—	—	—	—	3 560 EUR	—	—	—	—	—	—	—
Current liabilities	—	—	—	3 925 EUR	—	—	—	—	5 094 EUR	—	—	—	—	—	—	—
Revenue	—	4 640 EUR	—	—	—	—	—	—	—	—	—	5 252 EUR	—	—	—	—
Profit (loss)	0 EUR	3 518 EUR	0 EUR	—	0 EUR	3 518 EUR	0 EUR	0 EUR	—	0 EUR	0 EUR	4 206 EUR	0 EUR	0 EUR	4 206 EUR	0 EUR
Comprehensive income	—	3 575 EUR	—	—	—	—	—	—	—	—	—	3 985 EUR	—	—	—	—